Navigation Links
Organovo Reports Q2 2012 Financial Results, Provides Business Update
Date:8/15/2012

SAN DIEGO, Aug. 15, 2012 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQB: ONVO) ("Organovo") a three-dimensional biology company focused on delivering breakthrough 3-D bioprinting technology, today reported unaudited financial results for the period ended June 30, 2012.

(Logo:  http://photos.prnewswire.com/prnh/20120813/MM55537LOGO)

Organovo is focused on breakthrough 3D bioprinting technology to create tissue on demand for research and medical applications. The company's NovoGen MMX  Bioprinter() is part of a 3D human tissue generation platform that works across a broad array of tissue and cell types to recapitulate in vivo biology. Organovo's bioprinting technology has immediate applications in disease research, drug discovery and development, and toxicology testing. In the future, the Company believes that applications of this technology hold the promise to generate tissues for therapeutic uses.

Second quarter 2012 revenues increased approximately 49% above the same period in 2011. Collaborative research revenues for the second quarter increased approximately 81% over the same period of prior year revenues, but were partially offset by a reduction in grant revenues.  Loss from Operations for the second quarter was approximately $1,449,700. 

Recent Corporate Highlights
On July 17, 2012, Organovo announced the commencement of operations at its new, larger facility in San Diego, California.  The new facility has over three times the capacity of Organovo's previous headquarters and is expected to facilitate the Company's needs to grow staff and research and development output.

On July 9, 2012, Organovo announced the receipt of two issued patents.  The patents consisted of the issuance in the United States of a patent to which the Company owns the exclusive license from the University of Missouri, and the issuance in the United Kingdom of the Company's first assigned patent.

On July 9, 2012 Organovo announced the appointment of James T. Glover, former CFO of Beckman Coulter and Anadys Pharmaceuticals, to its Board of Directors.  Mr. Glover has been affirmed as an independent director by the Organovo Board of Directors, and the Company expects to attract additional independent directors as it grows.

On May 21, 2012, Organovo announced the hiring of Dr. Eric Michael David as Chief Strategy Officer.

On April 25, 2012, Organovo announced the hiring of Michael Renard as its Executive Vice President, Commercial Operations, and the promotion of Dr. Sharon Presnell to Chief Technology Officer.

The Company is performing on current contracts with Pfizer and United Therapeutics.  The Company expects to book revenue on both contracts in the second half of 2012.

"Organovo continues to deliver on plan," stated Keith Murphy, chief executive officer of Organovo. "Our growing team, seasoned leadership, and greater capacity in the new facility all point to a growth in our impactful research and development efforts, which will contribute to growth in long term shareholder value."

Financial Results
For the second quarter 2012 total revenues of approximately $259,000 were $85,600 or 49% above the approximately $173,300 in revenues for the same period in 2011. Collaborative research revenues for the second quarter of approximately $259,000 increased $115,600 or 81% over the same period of prior year revenues of approximately $143,400. That growth was partially offset by no grant or product revenues in the second quarter 2012, compared to approximately $30,000 of grant revenues in the prior year second quarter. 

Operating expenses increased approximately $1,061,600 or 164% in the second quarter 2012 over the second quarter 2011, from approximately $647,000 in 2011 to $1,708,600 in 2012. Most significantly, relative to the same period in the prior year, the Company invested in infrastructure and outside services to support its transition from private ownership to a publicly owned and traded corporation. As expected in such transition, incremental initiatives were established in investor outreach, corporate governance, and SEC financial reporting. Non-payroll related incremental public company expenses incurred in the second quarter 2012 over the second quarter 2011 was approximately $150,000.  There were no second quarter 2011 public company expenses. Moreover, the Company invested in building its executive, research, and development staff, increasing second quarter 2012 payroll related expenses by approximately $523,800 or 174% over the second quarter 2011.  Second quarter 2012 executive search fees were approximately $24,000, newly established fees to our non-employee board members were approximately $41,300 and additional space was rented to accommodate our growing administrative and research staff at an approximate incremental cost of $25,000 over the period in 2011.

The increase in other expenses for the second quarter 2012 over the second quarter 2011, an increase of approximately $33,876,600, was primarily related to the non-cash transaction costs associated with the warrants issued in our 2012 Private Placement. During the first quarter of 2012 we incurred costs due to the placement agent for the first quarter Private Placement fees of $1,617,629 and reimbursed expenses and legal fees of $166,310. In addition, we issued warrants to purchase 6,099,195 shares of our common stock to the placement agent and warrants to purchase 15,247,987 of our common stock to investors in the Private Placement. The warrants issued to the placement agent and Private Placement investors were determined to be derivative liabilities as a result of the anti-dilution provisions in the warrant agreements that may result in an adjustment to the warrant exercise price. We will revalue the derivative liability on each balance sheet date and will do so until the securities to which the derivatives liabilities relate are exercised or expire. The change in fair value of warrant liabilities for the three months ended June 30, 2012, was approximately $33,937,200. Other expenses for the three months ended June 30, 2011 of approximately $58,900 related to interest recorded on convertible notes payable.

 Organovo Holdings Inc. (A development stage company) Condensed Balance Sheets June 30, 2012December 31, 2011(Unaudited)(Audited)AssetsCurrent AssetsCash and cash equivalents$  8,469,312

$
339,607Inventory527,246

291,881Deferred financing costs—

318,843Prepaid expenses and other current assets204,488

79,874Total current assets9,201,046

1,030,205Fixed Assets - Net323,153

278,208Restricted Cash88,290

—Other Assets 96,923

100,419Total assets$  9,709,412

$
,408,832Liabilities and Stockholders' DeficitCurrent LiabilitiesAccounts payable$
259,518

$
57,560Accrued expenses406,371

437,837Deferred revenue223,117

152,500Accrued interest payable—

24,018Convertible notes payable, current portion—

703,833Total current liabilities889,006

1,975,748Warrant Liabilities80,577,988

1,266,869Total liabilities$ 81,466,994

$
3,242,617 

Commitments and Contingencies Stockholders' DeficitCommon stock, $0.001 par value; 150,000,000 shares authorized, 43,772,483 and 22,445,254 issued and outstanding at June 30, 2012 and December 31, 2011, respectively43,773

22,445Additional paid-in capital7,355,924

4,835,326Deficit accumulated during the development stage(79,157,279)

(6,691,556)Total stockholders' deficit

(71,757,582)

(1,833,785)Total Liabilities and Stockholders' Deficit$  9,709,412

$
,408,832 Organovo Holdings, Inc. (A development stage company) Unaudited Condensed Statements of Operations Three Months Ended
June 30, 2012Three Months Ended
June 30, 2011Six Months Ended
June 30, 2012Six Months Ended
June 30, 2011Period from
April 19, 2007
(Inception)
through
June 30, 2012
RevenuesProduct$
8212;

$
8212;

$
8212;

$
,000

$
223,500Collaborations258,975

143,375

378,975

217,740

1,142,063Grants—

30,000

56,924

664,112Total Revenues258,975

173,375

378,975

374,664

2,029,675Cost of product revenue—

—50,584

133,607Selling, general, and administrative expenses1,056,066

335,946

1,957,909

579,440

4,623,946Research and development expenses652,568

311,066

1,199,855

709,730

4,398,243Loss from Operations(1,449,659)

(473,637)

(2,778,789)

(965,090)

(7,126,121)Other Income (Expense)Fair value of warrant liabilities in excess of proceeds received

(19,019,422)

(19,019,422)Change in fair value of warrant liabilities

(33,937,175)

(47,442,994)

(47,449,563)Financing transaction costs in excess of proceeds received

(2,129,500)

(2,129,500)Interest expense—

(58,843)

(1,087,453)

(111,925)

(3,405,895)Interest income1,692

1,984

3,990Other expense—

(9,549)

(1,550)

(30,768)Total Other Income (Expense)(33,935,483)

(58,843)

(69,686,934)

(113,475)

(72,031,158)Net Loss$ (35,385,142)

$
(532,480)

$ (72,465,723)

$
(1,078,565)

$ (79,157,279)Net loss per common share - basic and diluted$
(0.82)

$
(0.05)

$
(1.96)

$
(0.10)Weighted average shares used in computing net loss per common share - basic and diluted43,029,026

11,546,910

36,974,745

11,175,474 Organovo Holdings, Inc. (A development stage company) Unaudited Condensed Statements of Cash Flows Six Months Ended
June 30, 2012Six Months Ended
June 30, 2011Period from
April 19, 2007
(Inception)
through
June 30, 2012Cash Flows From Operating ActivitiesNet loss$
(72,465,723)

$
(1,078,565)

$(79,157,279)Adjustments to reconcile net loss to net cash used in operating activities:Amortization of deferred financing costs 

318,843

438,296Depreciation and amortization38,728

32,430

195,056Amortization of debt discount896,167

2,083,735Interest accrued on convertible notes payable11,616

111,925

495,392Fair value of warrant liabilities in excess of proceeds

19,019,422

19,019,422Change in fair value of warrant liabilities

47,442,994

47,449,563Stock-based compensation42,642

1,882

59,591Warrants issued in connection with exchange agreement

527,629Increase (decrease) in cash resulting from changes in:Accounts receivable—

—Grants receivable

59,744

—Inventory(235,365)

(93,717)

(527,246)Prepaid expenses and other assets(124,614)

(10,835)

(217,620)Accounts payable(398,042)

213,828

259,518Accrued expenses(31,467)

28,918

406,371Deferred revenue

70,618

125,048

223,117Net cash used in operating activities(5,414,181)

(609,342)

(8,744,455)Cash Flows From Investing ActivitiesRestricted cash deposits(88,290)

(88,290)Purchases of fixed assets(80,177)

(9,286)

(507,000)Purchases of intangible assets—

(65,000)

(95,000)Net cash used in investing activities(168,467)

(74,286)

(690,290)Cash Flows From Financing ActivitiesProceeds from issuance of convertible notes payable—

298,700

4,630,000Proceeds from issuance of common stock and warrants13,822,600

13,822,600Proceeds from issuance of related party notes payable

150,000

250,000Repayment of related party notes payable—

(25,000)

(250,000)Repayment of convertible notes and interest payable(110,247)

(110,247)Deferred financing costs—

(6,415)

(438,296)Net cash provided by financing activities13,712,353

417,285

17,904,057Net Increase (Decrease) in Cash and Cash Equivalents8,129,705

(266,343)

8,469,312Cash and Cash Equivalents at Beginning of Period339,607

285,308

—Cash and Cash Equivalents at End of Period$
8,469,312

$
8,965

$  8,469,312About Organovo Holdings, Inc.
Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. The Company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types. Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine. Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development. Organovo's bioprinting technology can also be developed to create surgical tissues direct therapy. Organovo leads the way in solving complex medical research problems and building the future of medicine. For more information, please visit http://www.organovo.com.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.


'/>"/>
SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Organovo, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
2. Organovo Announces Two Issued Patents, First Company Patent and Key Founder Patent
3. Organovo Holdings Appoints James T. Glover to Board of Directors
4. ULURU Inc. Reports Second Quarter 2012 Financial Results
5. China Pharma Holdings, Inc. Reports Second Quarter 2012 Financial Results
6. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
7. Nephros Reports Second Quarter 2012 Financial Results
8. Tengion Reports Second Quarter 2012 Financial Results
9. Synthetic Biologics Reports Second Quarter 2012 Financial Results
10. Vermillion Reports Second Quarter 2012 Results
11. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... edge technology to revolutionize the emergency ambulance transport experience for the millions of ... of how Uber has disrupted the taxi industry through the use of technology. ...
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
Breaking Medicine News(10 mins):